{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:44:29Z","timestamp":1761518669083},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2000,10,1]],"date-time":"2000-10-01T00:00:00Z","timestamp":970358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":7023,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2000,10]]},"DOI":"10.1023\/a:1008351310818","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T14:41:38Z","timestamp":1040568098000},"page":"1249-1254","source":"Crossref","is-referenced-by-count":24,"title":["Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study"],"prefix":"10.1016","volume":"11","author":[{"given":"D.","family":"Mavroudis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Alexopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Ziras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Malamos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kouroussis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kakolyris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Agelaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Kalbakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Tsavaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Potamianou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Rigatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Georgoulias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1023\/A:1008351310818_bb0005","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/07357909909011727","article-title":"Taxanes in the treatment of breast cancer: A prodigy comes of age","volume":"17","author":"Miller","year":"1999","journal-title":"Cancer Invest"},{"key":"10.1023\/A:1008351310818_bb0010","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","article-title":"Paclitaxel by three-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumour efficacy and cardiac effects in a dose-finding and sequence-finding study","volume":"13","author":"Gianni","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008351310818_bb0015","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.1996.14.3.774","article-title":"Phase I\u2013II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony stimulating factor in patients with metastatic breast cancer","volume":"14","author":"Fisherman","year":"1996","journal-title":"J Clin Oncol"},{"issue":"3, Suppl 6","key":"10.1023\/A:1008351310818_bb0020","first-page":"105","article-title":"ECOG studies of paclitaxel and doxorubicin in advanced breast cancer","volume":"22","author":"Sledge","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008351310818_bb0025","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1200\/JCO.1996.14.10.2713","article-title":"Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer","volume":"14","author":"Holmes","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008351310818_bb0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0305-7372(93)90036-Q","article-title":"Epirubicin and doxorubicin: A comparison of their characteristics, therapeutic activity and toxicity","volume":"19","author":"Launchbury","year":"1993","journal-title":"Cancer Treat Rev"},{"key":"10.1023\/A:1008351310818_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0305-7372(83)80029-2","article-title":"4\u2019-Epi-doxorubicin, a new analogue of doxorubicin: A preliminary overview of preclinical and clinical data","volume":"10","author":"Ganzina","year":"1983","journal-title":"Cancer Treat Rev"},{"key":"10.1023\/A:1008351310818_bb0040","first-page":"337","article-title":"Phase II clinical evaluation of 4\u2019-epidoxorubicin","volume":"67","author":"Hurteloup","year":"1983","journal-title":"Cancer Treat Rev"},{"key":"10.1023\/A:1008351310818_bb0045","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1200\/JCO.1992.10.2.297","article-title":"Phase I\u2013II study of high-dose epirubicin in advanced non-small-cell lung cancer","volume":"10","author":"Feld","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008351310818_bb0050","first-page":"388","article-title":"Epirubicin high-dose therapy in advanced breast cancer","volume":"27","author":"Neri","year":"1989","journal-title":"Int J Clin Pharmacol TherTox"},{"key":"10.1023\/A:1008351310818_bb0055","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.1996.14.4.1146","article-title":"Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group","volume":"14","author":"Bastholt","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008351310818_bb0060","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1008295427877","article-title":"Doubling epirubicin dose intensity (100 mg\/m2 versus 50 mg\/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer","volume":"8","author":"Brufman","year":"1997","journal-title":"Ann Oncol"},{"issue":"4, Suppl 13","key":"10.1023\/A:1008351310818_bb0065","first-page":"11","article-title":"Docetaxel as single-agent therapy in metastatic breast cancer: Clinical efficacy","volume":"24","author":"Valero","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008351310818_bb0070","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1200\/JCO.1995.13.10.2643","article-title":"Docetaxel","volume":"13","author":"Cortes","year":"1995","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1023\/A:1008351310818_bb0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00001813-199608002-00003","article-title":"First-line treatment of metastatic breast cancer","volume":"7","author":"Trudeau","year":"1996","journal-title":"Anticancer Drugs"},{"issue":"4, Suppl 10","key":"10.1023\/A:1008351310818_bb0080","first-page":"18","article-title":"Docetaxel (Taxotcre) for the treatment of anthracy-cline-resistant breast cancer","volume":"24","author":"Ravdin","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008351310818_bb0085","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.1998.16.10.3362","article-title":"A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer","volume":"16","author":"Valero","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008351310818_bb0090","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomised trial of docetaxel versus doxorubicin in patients with metastatic breast cancer","volume":"17","author":"Chan","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008351310818_bb0095","first-page":"111a","article-title":"Single agent Taxol versus doxorubicin as first-line chemotherapy in advanced breast cancer. Final results of an EORTC randomised study with crossover","volume":"17","author":"Gamucci","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008351310818_bb0100","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.1999.17.5.1413","article-title":"Prospective randomised trial of docetaxel versus mitomycin plus vinblastine in metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy","volume":"17","author":"Nabholtz","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008351310818_bb0105","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a058903","article-title":"Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind","volume":"5","author":"Verweij","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008351310818_bb0110","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1023\/A:1026441804889","article-title":"Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study","volume":"10","author":"Kouroussis","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008351310818_bb0115","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer research","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1023\/A:1008351310818_bb0120","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1959","journal-title":"J Am Stat Assoc"},{"key":"10.1023\/A:1008351310818_bb0125","series-title":"The Analysis of Binary Data","author":"Cox","year":"1970"},{"key":"10.1023\/A:1008351310818_bb0130","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1200\/JCO.1999.17.12.3828","article-title":"Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: An Eastern Cooperative Oncology Group Study","volume":"17","author":"Sparano","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008351310818_bb0135","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1200\/JCO.1999.17.4.1132","article-title":"Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients","volume":"17","author":"Esposito","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008351310818_bb0140","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1200\/JCO.1996.14.2.422","article-title":"Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada-Clinical Trials Group","volume":"14","author":"Trudeau","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008351310818_bb0145","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1023\/A:1008370930599","article-title":"Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK","volume":"10","author":"O\u2019Brien","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008351310818_bb0150","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1023\/A:1026437731354","article-title":"Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer","volume":"10","author":"Pagani","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008351310818_bb0155","first-page":"151a","article-title":"Docetaxel in combination with epirubicin as first-line chemotherapy of metastatic breast cancer: Final results","volume":"17","author":"Kerbrat","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008351310818_bb0160","first-page":"117a","article-title":"Escalating doses of docetaxel and epirubicin as first-line therapy for metastatic breast cancer. A phase I\u2013II study of the National Cancer Institute of Canada-Clinical Trials Group","volume":"18","author":"Trudeau","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008351310818_bb0165","first-page":"118a","article-title":"Preoperative doce-taxel-epidoxorubicin in primary breast cancer","volume":"18","author":"Steger","year":"1999","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419556587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419556587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/11\/10\/1249\/19477735\/11-10-1249.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:20:31Z","timestamp":1582183231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419556587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2000,10]]}},"alternative-id":["S0923753419556587"],"URL":"https:\/\/doi.org\/10.1023\/a:1008351310818","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2000,10]]}}}